Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: Pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 997-1004

  Cable, Melissa ^a  

^a Discover Vision Centers   (United States)

Author keywords

Cataract; Inflammation; Macular volume; NSAIDs; Phacoemulsification; Retinal thickness

Indexed keywords

BROMFENAC; DIFLUPREDNATE; NEPAFENAC;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE INFLAMMATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANTATION; MACULAR VOLUME; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PILOT STUDY; POSTOPERATIVE CARE; RETINAL THICKNESS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84865634943     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S32179     Document Type: Article

References (32)

1. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122(4):487-494.
2. Desai P, Minassian DC, Reidy A. National cataract surgery survey 1997-1998: a report of the results of the clinical outcomes. Br J Ophthalmol. 1999;83(12):1336-1340.
3. Mangione CM, Phillips RS, Lawrence MG, Seddon JM, Orav EJ, Goldman L. Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol. 1994;112(11):1419-1425.
4. McGwin G Jr, Scilley K, Brown J, Owsley C. Impact of cataract surgery on self-reported visual difficulties: comparison with a no-surgery reference group. J Cataract Refract Surg. 2003;29(5):941-948.
5. Schein OD, Steinberg EP, Javitt JC, et al. Variation in cataract surgery practice and clinical outcomes. Ophthalmology. 1994;101(6):1142-1152.
6. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21(7):1131-1137.
7. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33(9):1546-1549.
8. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108-133.
9. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1-11.
10. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin. 1996;36(1):195-206.
11. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217(2):89-98.
12. Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30(4):752-760.
13. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2000;11(1):3-6.
14. Sourdille P, Santiago PY. Optical coherence tomography of macular thickness after cataract surgery. J Cataract Refract Surg. 1999;25(2):256-261.
15. Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146(4):554-560.
16. Blumenkranz MS, Haller JA, Kuppermann BD. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina. 2010;30(7):1090-1094.
17. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.
18. Kida T, Ogawa T, McNamara TR, Song CK, Gow JA. Evaluations of the human COX-2inhibition for amfenac, bromfenac, diclofenac, and ketorolac. Paper presented at: American Society of Cataract and Refractive Surgery Symposium on Cataract, IOL, and Refractive Surgery; April 27-May 2, 2007; San Diego, CA.
19. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24(4):357-370.
20. Bucci FA Jr, Waterbury LD. Prostaglandin E2inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther. 2011;28(12):1089-1095.
21. Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology. 2007;114(9):1653-1662.
22. Silverstein SM, Cable MG, Sadri E, et al. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011;27(9):1693-1703.
23. Nardi M, Lobo C, Bereczki A, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. Clin Ophthalmol. 2007;1(4):527-533.
24. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33(1):53-58.
25. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33(9):1539-1545.
26. Bucci F Jr, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg. 2008;34(9):1509-1512.
27. Kawaguchi T, Kida T, Nemoto S, et al. Effect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery. Nihon Ganka Kiyo. 2003;54(4):276-279. Japanese.
28. Bromday™ (bromfenac ophthalmic solution) 0.09% [package insert]. Irvine, CA: ISTA Pharmaceuticals Inc; 2011.
29. Nevanac® (nepafenac ophthalmic suspension) 0.1% [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 2011.
30. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol. 2000;44(1):58-67.
31. Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32(3):241-247.
32. Biro Z, Balla Z, Kovacs B. Change of foveal and perifoveal thickness measured by OCT after phacoemulsification and IOL implantation. Eye (Lond). 2008;22(1):8-12.